A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

I4V-MC-JAHG -

The purpose of this study is to evaluate the safety and effectiveness of baricitinib in people with eczema.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Atopic Dermatitis
What the trial is testing?
Baricitinib, Triamcinolone
Could I receive a Placebo?
Yes
Enrollment Goal
124
Trial Dates
Feb 1, 2016 - Mar 1, 2017
How long will I be in the trial?
Your participation could last up to 28 weeks and include 8 visits to the study center.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.